Biohaven Pharmaceutical Holding Total Assets 2016-2021 | BHVN

Biohaven Pharmaceutical Holding total assets from 2016 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Biohaven Pharmaceutical Holding total assets for the quarter ending September 30, 2021 were $1.131B, a 44.65% increase year-over-year.
  • Biohaven Pharmaceutical Holding total assets for 2020 were $0.687B, a 99.55% increase from 2019.
  • Biohaven Pharmaceutical Holding total assets for 2019 were $0.344B, a 18.71% increase from 2018.
  • Biohaven Pharmaceutical Holding total assets for 2018 were $0.29B, a 97.44% increase from 2017.
Biohaven Pharmaceutical Holding Annual Total Assets
(Millions of US $)
2020 $687
2019 $344
2018 $290
2017 $147
2016 $27
2015 $2
Biohaven Pharmaceutical Holding Quarterly Total Assets
(Millions of US $)
2021-09-30 $1,131
2021-06-30 $846
2021-03-31 $1,003
2020-12-31 $687
2020-09-30 $782
2020-06-30 $424
2020-03-31 $533
2019-12-31 $344
2019-09-30 $439
2019-06-30 $491
2019-03-31 $245
2018-12-31 $290
2018-09-30 $195
2018-06-30 $239
2018-03-31 $126
2017-12-31 $147
2017-09-30 $185
2017-06-30 $214
2017-03-31 $60
2016-12-31 $27
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.002B $0.064B
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69